Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | MST1R | Q04912 | 1/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.45 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450993 | 1.00 | CLK4 (0.46) | CLK4DYRK1BNTRK2TYRO3FYN | |
| SCHEMBL31098601 | 0.88 | SMYD3 (0.53) | CLK4CASP3NTRK1PRKACAFLT3 | |
| SCHEMBL4611577 | 0.88 | SMYD3 (0.53) | CLK4CASP3NTRK1PRKACAFLT3 | |
| SCHEMBL14395236 | 0.85 | PARP10 (0.56) | CASP3PRKACACA12CA9CA1 | |
| SCHEMBL20446302 | 0.82 | NPC1 (0.53) | CLK4DYRK1BNTRK2TYRO3FYN | |
| SCHEMBL5879567 | 0.80 | TDP2 (0.61) | CLK4DYRK1BNTRK2TYRO3FYN | |
| SCHEMBL27491542 | 0.79 | PRF1 (0.55) | CLK4DYRK1BNTRK2TYRO3FYN | |
| SCHEMBL28367558 | 0.78 | CLK4 (0.46) | CLK4DYRK1BNTRK2TYRO3FYN | |
| SCHEMBL29873105 | 0.78 | CLK4 (0.49) | CLK4DYRK1BNTRK2TYRO3FYN | |
| SCHEMBL24348699 | 0.77 | CA12 (0.44) | CLK4DYRK1BNTRK2TYRO3FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563245-B | Substituted pyrrolidines and their use in medicine | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-113563245-A | Substituted pyrrolidine compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| CN-111094292-A | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018218051-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2017182418-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | CLK4 1454/4885DYRK1B 1330/4885NTRK2 3519/4885 |
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | RIPK2, RIPK1, RIPK4 | CLK4 1298/4885DYRK1B 1576/4885NTRK2 1332/4885 |
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | CLK4 1866/4885DYRK1B 1700/4885NTRK2 581/4885 |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | CLK4 1298/4885DYRK1B 1576/4885NTRK2 1332/4885 |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | CLK4 1866/4885DYRK1B 1700/4885NTRK2 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.